Literature DB >> 10811539

Distinction between preclinical Alzheimer's disease and depression.

P J Visser1, F R Verhey, R W Ponds, A Kester, J Jolles.   

Abstract

OBJECTIVE: To assess the prevalence of depression in subjects with preclinical Alzheimer's disease (AD) and to investigate the possibility of differentiating subjects with preclinical AD and depression from subjects with depression-related cognitive impairment.
DESIGN: A prospective, observational cohort study.
SETTING: An outpatient memory clinic of a university-affiliated hospital. PARTICIPANTS: Nondemented subjects with cognitive impairment older than 55 years (n = 111) without neurological or somatic causes for the cognitive impairment. MEASUREMENTS: At baseline, data were collected on patient characteristics, the severity of depression, and cognitive functioning. The course of the cognitive impairment and the presence of dementia were assessed after 2 and 5 years.
RESULTS: Twenty-five subjects had preclinical dementia with Alzheimer's type dementia at follow-up. Sixty percent of these subjects (n = 15) were depressed at baseline. Subjects with depression and preclinical AD had at baseline a poorer performance on the cognitive tasks and were older than the subjects with depression-related cognitive impairment. Logistic regression with backward step selection selected age and memory performance as the best predictors for Alzheimer's type dementia in the depressed subjects. The specificity of these predictors for the diagnosis of future Alzheimer's type dementia in depressed subjects was 94%, sensitivity was 90%, positive predictive value was 90%, and negative predictive value was 94%.
CONCLUSIONS: Depression is common in preclinical AD. Depressed subjects with preclinical AD can be accurately differentiated from subjects with depression-related cognitive impairment by age and the severity of the memory impairment. Research that aims to investigate preclinical AD should not exclude a priori subjects with depression inasmuch as preclinical AD is often accompanied by depression.

Entities:  

Mesh:

Year:  2000        PMID: 10811539     DOI: 10.1111/j.1532-5415.2000.tb04992.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  23 in total

1.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

Review 2.  Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience.

Authors:  Anand Kumar; Olusola Ajilore; Vladimir Kepe; Jorge R Barrio; Gary Small
Journal:  Int J Geriatr Psychiatry       Date:  2008-06       Impact factor: 3.485

3.  Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia.

Authors:  J Saxton; B E Snitz; O L Lopez; D G Ives; L O Dunn; A Fitzpatrick; M C Carlson; S T Dekosky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-03-11       Impact factor: 10.154

4.  Selectivity of executive function deficits in mild cognitive impairment.

Authors:  Jason Brandt; Eleni Aretouli; Eleanor Neijstrom; Jaclyn Samek; Kevin Manning; Marilyn S Albert; Karen Bandeen-Roche
Journal:  Neuropsychology       Date:  2009-09       Impact factor: 3.295

5.  Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment.

Authors:  P J Visser; F R J Verhey; P A M Hofman; P Scheltens; J Jolles
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

6.  Neuropsychological indicators of preclinical Alzheimer's disease among depressed older adults.

Authors:  Nicole C Rushing; Natalie Sachs-Ericsson; David C Steffens
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2013-05-09

7.  Relational memory and self-efficacy measures reveal distinct profiles of subjective memory concerns in older adults.

Authors:  Heather D Lucas; Jim M Monti; Edward McAuley; Patrick D Watson; Arthur F Kramer; Neal J Cohen
Journal:  Neuropsychology       Date:  2016-04-07       Impact factor: 3.295

8.  Neuropsychological prediction of conversion to dementia from questionable dementia: statistically significant but not yet clinically useful.

Authors:  J Tian; R S Bucks; J Haworth; G Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

Review 9.  Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia.

Authors:  Howard Chertkow; Fadi Massoud; Ziad Nasreddine; Sylvie Belleville; Yves Joanette; Christian Bocti; Valérie Drolet; John Kirk; Morris Freedman; Howard Bergman
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

10.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.